BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Liquid biopsies are revolutionizing clinical trials\, emerging
  as a game-changing diagnostic tool for monitoring molecular residual dis
 ease and detecting disease resistance. This breakthrough enables precise 
 patient stratification\, ensuring they receive the most effective and saf
 e treatments. In 2024\, a wave of collaborations has surged\, propelling 
 the use of liquid biopsies for MRD testing to new heights. The FDA's reco
 gnition of MRD as an endpoint in multiple myeloma marks a monumental leap
  forward for the field\, heralding a new era in patient care and therapeu
 tic development.\n\nThe 3rd Liquid Biopsy Surveillance Summit returns as 
 the leading East Coast forum solely dedicated to MRD detection in clinica
 l trials to improve stage response monitoring to get patients earlier acc
 ess to precision treatments.\n\nExpect to hear critical insights from lea
 ding biopharma\, oncologists and diagnostic providers to utilise liquid b
 iopsies as surrogate endpoints in clinical trials\, guide dosing decision
 s and enable the development of precise drugs for patients with unmet nee
 ds in oncology and beyond.\n\nJoin your peers from Biomarker\, Translatio
 nal and Clinical Development teams to more accurately monitor drug respon
 se through MRD assessments for improved treatment regimens from early to 
 late stage clinical trials to improve patient outcomes.\n\nURLs:Website:&
 nbsp\;https://go.evvnt.com/2612043-0?pid=185Tickets:&nbsp\;https://go.evv
 nt.com/2612043-2?pid=185Brochure:&nbsp\;https://go.evvnt.com/2612043-3?pi
 d=185\n\nPrices:Drug Developer and Researchers - Conference Only: USD 0.5
 0\,Solution Providers - Conference Only: USD 3699.00\n\nSpeakers:&nbsp\;A
 ngela Silvestro\, Director - Companion Diagnostics\, GSK\, David Yu\, Dir
 ector - Precision Medicine and Translational Medicine\, Bristol Myers Squ
 ibb\, Gabriele Allegri\, Vice President - Global Commercial Precision Med
 icine\, Johnson and Johnson Innovative Medicine\, J.D. Schonhoft\, Associ
 ate Director - Translational Medicine\, Repare Therapeutics\, Janet Jin\,
  Executive Director - Precision Medicine\, Clinical Diagnostics and Imagi
 ng\, Amgen\, Jean-Francois Martini\, Executive Director - Translational O
 ncology Lead\, Global Product Development - Oncology\, Pfizer\, Jessica P
 iel\, Senior Director and Head - Translational Sciences\, Foghorn Therape
 utics\, Jonathan Beer\, Senior Director - Diagnostic Sciences\, Bristol M
 yers Squibb\, Judy Keen\, Director - Translational Science\, Cancer\, Fou
 ndation for the NIH\, Kris Sachsenmeier\, Vice President - Head of Transl
 ational Sciences\, Lauren Leiman\, Executive Director\, BLOODPAC\, Minaks
 hi Guha\, Associate Director - Precision Medicine\, Companion Diagnostics
  and Liquid Biopsy Lead\, Takeda\, Miriam Colindres Rojas\, Associate Dir
 ector - Diagnostics and Analytics Strategy\, BioNTech\, Nisha Rajagopal\,
  Associate Director - Data Science\, Novartis\, Piero Ricchiuto\, Head of
  Clinical Bioinformatics and Biomarker Discovery\, Alexion Pharmaceutical
 s\, Raluca Budiu-Predoiu\, Director - Precision Medicine\, AbbVie\, Shou-
 Ching Jaminet\, Co-Founder\, Angiex\, Simon Heeke\, Assistant Professor -
  Head of Liquid Biopsy Translational Working Group\, MD Anderson Cancer C
 enter\, Xintong Chen\, Director - Translational Medicine Strategy\, Astra
 Zeneca\, Yinghui Zhou\, Head - Translational Science\, Synnovation Therap
 eutics\, Zheng Feng\, Director and Head - Clinical Genomics Clinical Biom
 arker Technologies\, EMD Serono\n\nCategory:&nbsp\;Conferences | Science\
 , Health and Medicine | Pharmaceuticals\n\nDate and Time:&nbsp\;21st Nove
 mber 2024 at 8:00 am to 22nd November 2024 at 3:45 pm\n\nVenue details:&n
 bsp\;The Westin Boston Seaport District\, 425 Summer Street\, Boston\, Ma
 ssachusetts\, 02210\, United States\n
DTEND:20241122T154500
DTSTAMP:20260512T214303Z
DTSTART:20241121T080000
LOCATION:The Westin Boston Seaport District\, 425\, Summer Street\, Boston
 \, Massachusetts\, 02210\,
SEQUENCE:0
SUMMARY:Liquid biopsies are revolutionizing clinical trials\, emerging as 
 a game-changing diagnostic tool for monitoring molecular residual disease
  and dete...
UID:975885a2-5525-4862-bbc6-8434916453bc
END:VEVENT
END:VCALENDAR